Porownywarka
Modified GRF (1-29) vs Ipamorelin side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Modified GRF (1-29) | Ipamorelin |
|---|---|---|
| Kategoria | Hormon wzrostu | Hormon wzrostu |
| Znany tez jako | CJC-1295 without DAC, CJC-1295 No DAC, Tetrasubstituted GRF (1-29) | IPAM, NNC 26-0161 |
| Zatwierdzony przez FDA | Nie | Nie |
| Status kliniczny | The source characterizes the program as investigational and Phase II-discontinued. It reports Category 2 removal in September 2024 for PCAC review, a Category 1 reclassification expectation on April 15, 2026, and PCAC review on July 23–24, 2026; it says Category 2 remains pending a formal FDA rule. Nie dotyczy | Investigational; Phase II trials discontinued. Listed as FDA Category 2 pending possible reclassification, with formal status not changed in the source.
|
| Czego oczekiwac | The source lists growth hormone optimization, muscle gain, and fat loss as research interests; it does not establish those benefits. | Anti-aging, muscle building, sleep quality, recovery |
| Jak dziala | CJC-1295 is described as a synthetic modification of GHRH(1-29). The supplied material says it activates GHRH receptors on pituitary somatotrophs, increasing pituitary GH release, with hepatic IGF-I production following the GH rise. Native GHRH is described as being degraded within minutes. In the DAC variant, a reactive moiety is reported to attach covalently to circulating albumin after injection, reducing breakdown. The no-DAC form, Modified GRF 1-29, lacks this attachment and is reported to act for about 30 minutes. The described pathway depends on residual pituitary capacity for GH production. | Ipamorelin is reported to activate GHS-R1a, the ghrelin or growth hormone secretagogue receptor, on somatotroph cells in the anterior pituitary. The source links this receptor activity to Gq/phospholipase C signaling, IP3 generation, intracellular calcium release, and pulsatile release of stored growth hormone. It also describes ipamorelin as relatively selective in early characterization, with GH-releasing doses not meaningfully increasing ACTH, cortisol, prolactin, FSH, LH, or TSH. Because the mechanism relies on pituitary GH stores, the source indicates that pituitary function and normal feedback biology remain relevant to the response. |
| Typowe dawkowanie | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) · Daily (no DAC) or 1-2x weekly (with DAC) | 200-300 mcg 2-3x daily · 2-3x daily |
| Dawkowanie z badań | CJC-1295 DAC: 1-2mg weekly · 8-12 weeks · Subcutaneous injection | 100-300 mcg per injection · 8-12 weeks typical · Subcutaneous injection |
| Typowy czas trwania | Duration is supplied in the research dosing row. | 8-12 weeks typical |
| Podanie | Subcutaneous route | Subcutaneous injection |
| Timing | Before bed Take on empty stomach | Before bed or morning, fasted Fasted timing reported |
| Poziom dowodów | Badania kliniczne | Badania kliniczne |
| Mozliwe skutki uboczne |
+6 więcej
|
+6 więcej
|
| Podsumowanie researchu | Evidence reviewed for CJC-1295 separates pharmacokinetic findings from clinical outcomes. The DAC form is described as having a half-life of roughly 6 to 8 days, whereas the non-DAC form is described as acting for about 30 minutes. In the 2006 randomized ascending-dose study, one injection was associated with GH elevation lasting at least 6 days and IGF-I elevation for 9 to 11 days; repeat dosing produced cumulative hormone effects. A mouse experiment reported restored growth with daily exposure. The material does not provide large, long-term human trials demonstrating fat loss or muscle gain. Development stopped after Phase II, and the reported trial death was attributed by the treating physician to pre-existing coronary disease, an attribution not independently confirmed. | The source identifies Raun et al. 1998 as early foundational work and describes characterization across rats, pigs, and isolated pituitary cells. It reports that ipamorelin released GH without corresponding ACTH or cortisol increases at doses above the GH-release threshold. The source also notes that human development reached Phase II for postoperative ileus before being discontinued for insufficient efficacy. For popular wellness uses such as anti-aging, fat loss, muscle gain, or recovery, the source states that large peer-reviewed human randomized trials are not available and that these claims are extrapolated from mechanism rather than established outcomes. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.